MedPacto to Present Additional Osteosarcoma Clinical Results for "Vactosertib" at US SITC
MedPacto, an innovative new drug development company, announced on October 17 that it will present interim results from its Phase 1 clinical trial of the immuno-oncology candidate "Vactosertib" for osteosarcoma at the "Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting" to be held in Maryland, United States, from November 7 to 9.
The Phase 1 clinical trial results for MedPacto's "Vactosertib" in osteosarcoma have been selected for the "Late Breaking Abstract (LBA)" track at SITC. The LBA track is known for its more rigorous review process compared to regular abstracts and is reserved for innovative achievements based on the latest clinical data.
A MedPacto representative stated, "The selection of Vactosertib for the LBA track at SITC is international recognition of its clinical value and commercialization potential," adding, "We will release additional, improved interim data compared to the initial clinical results."
MedPacto is currently conducting clinical trials in both Korea and the United States for adult and adolescent osteosarcoma patients. In June, the company released initial data showing that monotherapy with "Vactosertib" achieved a partial response (PR) rate of over 35% in patients with relapsed or refractory osteosarcoma.
Prior to SITC, MedPacto will also participate in "BIO Europe Fall 2025," Europe's largest bio partnering event, to be held in Vienna, Austria, on November 3.
MedPacto President Woo Jungwon and US branch head Kim Saerom will attend in person to explore the potential for technology transfer of "Vactosertib" through partnerships with global pharmaceutical companies.
Hot Picks Today
"Could I Also Receive 370 Billion Won?"... No Limit on 'Stock Manipulation Whistleblower Rewards' Starting the 26th
- Samsung Electronics Labor-Management Reach Agreement, General Strike Postponed... "Deficit-Business Unit Allocation Deferred for One Year"
- "From a 70 Million Won Loss to a 350 Million Won Profit with Samsung and SK hynix"... 'Stock Jackpot' Grandfather Gains Attention
- "Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- "Who Is Visiting Japan These Days?" The Once-Crowded Tourist Spots Empty Out... What's Happening?
Osteosarcoma is a rare malignant tumor that develops in bone and cartilage. Although combination chemotherapy is used as the standard treatment, there are limitations in improving treatment efficacy and survival rates. The medical community expects that the global market will grow significantly if new therapies are developed.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
